BRAF and neoplasm: Other factors such as the tumoral immune cell infiltration, tumor mutational burden, and some tumor specific mutations [e.g. BRAF-mutant non-small cell lung cancer (NSCLC) (10)], have also been associated with favorable treatment response (11).